Carobbio, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.359
NA - Nord America 3.688
EU - Europa 1.615
SA - Sud America 693
AF - Africa 82
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 11.450
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.594
CN - Cina 2.216
SG - Singapore 1.359
BR - Brasile 526
HK - Hong Kong 514
VN - Vietnam 457
KR - Corea 425
IT - Italia 304
FI - Finlandia 298
GB - Regno Unito 297
RU - Federazione Russa 163
FR - Francia 131
SE - Svezia 124
AR - Argentina 84
ID - Indonesia 79
BD - Bangladesh 68
DE - Germania 62
IN - India 56
NL - Olanda 50
LT - Lituania 43
MX - Messico 40
PK - Pakistan 37
CA - Canada 33
ZA - Sudafrica 30
JP - Giappone 29
IQ - Iraq 23
AT - Austria 22
EC - Ecuador 21
ES - Italia 21
PL - Polonia 21
UA - Ucraina 20
CO - Colombia 18
MA - Marocco 12
CL - Cile 11
UZ - Uzbekistan 11
CZ - Repubblica Ceca 10
PY - Paraguay 10
GR - Grecia 9
TN - Tunisia 9
AU - Australia 7
CR - Costa Rica 7
JM - Giamaica 7
NP - Nepal 7
PE - Perù 7
TR - Turchia 7
ET - Etiopia 6
KE - Kenya 6
PH - Filippine 6
SA - Arabia Saudita 6
VE - Venezuela 6
HR - Croazia 5
JO - Giordania 5
UY - Uruguay 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
BO - Bolivia 4
CH - Svizzera 4
DZ - Algeria 4
EG - Egitto 4
GE - Georgia 4
IE - Irlanda 4
IL - Israele 4
KZ - Kazakistan 4
MY - Malesia 4
RO - Romania 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
LB - Libano 3
NZ - Nuova Zelanda 3
OM - Oman 3
QA - Qatar 3
RS - Serbia 3
AM - Armenia 2
BH - Bahrain 2
HN - Honduras 2
NG - Nigeria 2
NO - Norvegia 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AO - Angola 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
GY - Guiana 1
HT - Haiti 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LR - Liberia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
PA - Panama 1
PF - Polinesia Francese 1
PG - Papua Nuova Guinea 1
Totale 11.440
Salva come PNG Salva come JPEG
Città #
Hefei 1.544
Santa Clara 1.276
Singapore 763
San Jose 518
Hong Kong 508
Seoul 423
Ashburn 393
Helsinki 283
London 238
Ho Chi Minh City 182
Council Bluffs 122
Chicago 107
The Dalles 106
Hanoi 95
Kent 90
Lauterbourg 90
Beijing 84
Los Angeles 72
Moscow 64
Jakarta 58
Milan 57
Redondo Beach 46
Salt Lake City 46
Buffalo 45
New York 44
São Paulo 42
Shanghai 37
Amsterdam 29
Dallas 26
Da Nang 24
Nuremberg 23
Rio de Janeiro 21
Elk Grove Village 20
Rome 18
Denver 17
Tokyo 17
Brooklyn 16
Frankfurt am Main 16
Johannesburg 16
Tampa 16
Warsaw 16
Curitiba 15
Haiphong 15
Karachi 15
Ealing 13
Tianjin 13
Guangzhou 12
Phoenix 12
Atlanta 11
Boardman 11
Boston 11
Brasília 11
Campinas 11
Chennai 11
Guayaquil 11
Lappeenranta 11
Vienna 11
Baghdad 10
Dhaka 10
Houston 10
Tashkent 10
Mexico City 9
Assago 8
Biên Hòa 8
Chengdu 8
Dulles 8
Florence 8
Fort Lauderdale 8
Lahore 8
Miami 8
Ninh Bình 8
Orem 8
Paris 8
Salvador 8
Wilmington 8
Buenos Aires 7
Cape Town 7
Hillsboro 7
Maceió 7
Montreal 7
Porto Alegre 7
Shenzhen 7
Sterling 7
Addis Ababa 6
Baton Rouge 6
Bogotá 6
Caxias do Sul 6
Falkenstein 6
Lancaster 6
Leander 6
Miano 6
Poplar 6
Quito 6
Reggio Emilia 6
Roxbury 6
Seattle 6
Stockholm 6
Thái Bình 6
Toronto 6
Amman 5
Totale 8.112
Salva come PNG Salva come JPEG
Nome #
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer 179
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 165
Association between cuffed tracheal tube use and reduced ventilator-associated pneumonia and conditions after elective cardiac surgery in infants and young children 164
A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 151
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 149
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 145
Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study 143
Long-term follow-up of recovered MPN patients with COVID-19 143
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms 142
Masked polycythemia vera (mPV): results of an international study 134
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment 133
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 131
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 130
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 130
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study 128
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study 127
Adherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study 126
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) 125
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes 124
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study 123
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 122
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients 121
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status 120
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia 120
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists 116
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 114
Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn’s Disease: Determinants of Higher Adherence and Response 114
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 113
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 112
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia 111
Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke? 111
ASXL1 mutations in primary and secondary myelofibrosis 111
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera 111
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis 110
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis 110
Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts 108
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia 108
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials 107
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria 107
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 106
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study 106
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 105
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients 105
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 103
Thrombosis in primary myelofibrosis: incidence and risk factors 103
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 102
Masked polycythemia vera diagnosed according to WHO and BCSH classification 102
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 101
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19 100
Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study) 99
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study 98
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600 98
The impact of a standardized perioperative management on hospital mortality after the Norwood procedure in a low volume center: results and perspectives 97
Risk factors for intubation in severe bronchiolitis: a useful tool to decide on an early intensive respiratory support 97
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 97
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera 96
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 96
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients 95
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status 95
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis 95
Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria 95
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach 94
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin 94
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial 93
Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device 93
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 92
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy 92
Splanchnic Vein Thromboses associated with Myeloproliferative Neoplasms: an international, retrospective study on 518 cases 91
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study 91
Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials 91
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera 90
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology 90
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 89
Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit 89
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment 89
Second versus first wave of COVID-19 in patients with MPN 88
Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI) 88
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients 88
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases 87
Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing 87
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy 86
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases 86
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis 84
Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review 84
Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification 84
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics 83
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis 83
ACE inhibitors and cytoreductive therapy in polycythemia vera 83
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria 82
Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients 82
Second cancers in MPN : Survival analysis from an international study 82
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) 82
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients 81
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma 81
The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis 80
Practice-relevant revision of IPSET-thrombosis based on 1019 patients with 80
Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate? 79
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study 78
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients 78
Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis 77
Totale 10.480
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.666
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.666
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024415 0 0 0 0 0 0 0 210 37 17 64 87
2024/20253.911 40 25 28 270 745 769 220 47 405 144 592 626
2025/20267.280 703 728 1.034 1.089 391 423 988 291 845 602 186 0
Totale 11.606